3-T Magnetic Resonance Diffusion-Weighted Imaging (DWI) for Characterization of Hepatic Masses

Abdulghaffara W1,2, Nasr M1,2, Shahin W1,4, El-Tantawy AM2 and Akl TH3

1Annoor Specialist Hospital Housing, Moudaffa road, Box 6251, Makkah, Saudi Arabia
2Department of Diagnostic and Interventional Radiology, Mansoura University Hospital, 35112, 12 El-Gomhoreya Street, Mansoura, Egypt
3Faculty of Medicine, Oncology Centre, Mansoura University, 12 El-Gomhoreya street, Mansoura, Egypt
4Gastroenterology Department, Banha University, Egypt

Received date: December 23, 2016; Accepted date: January 24, 2017; Published date: January 30, 2017

Abstract

Objective: To evaluate the role of DWI and ADC in differentiating benign from malignant hepatic masses

Materials and methods: Forty-one patients with fifty-two focal hepatic masses were included in our study. MRI was done using coronal T2-weighted single-shot turbo spin-echo, breath hold axial 3-D gradient-echo, breath hold 2-D gradient-echo in and out-of-phase, respiratory-triggered axial turbo spin-echo T2 sequence with fat saturation, followed by free breathing Diffusion-weighted MR imaging using a single-shot spin-echo planar imaging sequence and finally triphasic-MRI.

Results: Forty-one patients (Fifty-two lesions) were included in our study. Twenty-three lesions were benign; eight of them were cysts (mean ADC values of 3.15 ± 0.34 × 10⁻³ mm²/s) and fifteen lesions were hemangiomas (mean ADC values of 2.10 ± 0.25 × 10⁻³ mm²/s). Twenty-nine lesions were malignant; twelve HCC lesions (mean ADC values of 1.10 ± 0.32 × 10⁻³ mm²/s) and seventeen masses were metastasis (mean ADC values of 0.96 ± 0.23 × 10⁻³ mm²/s). Sensitivity and specificity of DWI in differentiating malignant from benign hepatic masses were 96.8% and 95.7% respectively.

Conclusion: DWI is an easy technique to obtain and to be evaluated. ADC values can differentiate benign from malignant liver masses with high sensitivity and specificity.

Keywords: Magnetic resonance imaging; Diffusion weighted imaging; Apparent diffusion coefficient; Liver neoplasms

Introduction

The progress of imaging modalities increases the sensitivity of hepatic focal lesions detection during routine radiological examination. Benign hepatic focal lesions arises usually on top of non-cirrhotic liver. Hemangioma is the most common benign hepatic lesion followed by focal nodular hyperplasia and adenomas [1,2]. Metastasis is the commonest malignant hepatic lesion arising on top of non-cirrhotic liver. On the other hand, hepatocellular carcinoma and intra-hepatic cholangiocarcinoma arise more on top of chronic liver diseases. The progression of imaging modalities including functional imaging increased accuracy characterization of hepatic lesions, therefore decreased the rate of unnecessary biopsies for benign lesions which is related to high incidence of morbidity (2.0% to 4.8%) and mortality (about 0.05%) [3,4]. Ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) are the most widely used hepatic imaging modalities. Most of the published studies concluded their similar diagnostic accuracy in the assessment of focal hepatic lesions with no significant difference in their specificities ranging from 82%-89% [4,5].

Over the last few years, several published series have studied the role of DWI in the evaluation of different hepatic lesions. DWI is more sensitive than T2-weighted sequences [6-9] and than different super paramagnetic iron oxide, enhanced MR studies in the detection and accurate characterization of liver lesions [10]. DWIs has a great role in detection and proper characterization of small focal hepatic lesions which makes DWI superior than other modalities [6,8,10]. High SNRs and high lesion-to-liver signal intensity ratios are seen better at low b values alleviating the depiction of focal liver lesions. Also, black blood effect of diffusion-weighted images help in differentiating small focal lesions from intra-hepatic vessels. DWI is helpful in early detection of small hepatocellular carcinomas (HCCs) in patients with liver cirrhosis due to less clarity of parenchymal heterogeneity and less signal intensity of the cirrhotic liver related to regeneration nodules and fibrosis on DWI in comparison to other T2-weighted images [11]. The differentiation between malignant and benign focal hepatic lesions is a diagnostic dilemma. Therefore, in a trial to improve the characterization of hepatic lesions, new evolving techniques of pre-existing modalities, such as MRI, computed tomography (CT) and ultrasonography are being increasingly developed. Recently, some researches have noted that the apparent diffusion coefficient (ADC), which is one of calculated parameters of DWI, is a useful new technique in differentiating benign and malignant lesions in the liver [12].
The diffusion coefficient is measured by the degree of molecular mobility of water particles therefore, it varies according to tissue properties including size of the extracellular space (which reflects the rate of unhindered moving water protons), viscosity and cellularity [13]. Measuring diffusion coefficients has been shown to be helpful for the characterization of focal and diffuse diseases of the liver [14,15].

Objective

The aim of our study was to assess the role of DWI and the ADC in differentiating between benign and malignant hepatic masses.

Materials and Methods

Patient populations

Between February 2011 and June 2013, Forty-one patients (25 males and 16 females with age range, 21–67 years; mean age, 49 years) with focal hepatic masses were included in our study. We apply our study on all patients referred to our department for MRI of the liver at the period of the study. Patients were imaged using conventional MRI, DWI and triphasic-MRI before biopsy of liver masses. Written informed consent was obtained from all patients before MRI.

MRI techniques

Magnetic resonance imaging was performed using a 3-T unit (Magnetom Skyra; Siemens Medical Solutions, Germany), equipped with high-performance gradients and a six-element phased-array body coil. Before diffusion-weighted imaging the following sequences are done:

1. Coronal T2-weighted half-Fourier single-shot turbo spin-echo (HASTE) using repetition time (TR)=1200 ms, echo time (TE)=95 ms, flip angle (FA)=150, matrix=256 × 154, slice thickness=5 mm, interslice gap=30%, field of view (FOV)=40 cm, and averages=1;
2. Breath hold axial 3-D gradient-echo T1-weighted (volumetric interpolated breath-hold examination=VIBE) using TR=4.96 ms, TE=2.38 ms, FA=10, matrix=256 × 166, slice thickness=3.0 mm, interslice gap=20%, FOV=40 cm, and averages=1;
3. 2-D gradient-echo T1 in-phase and out-of-phase using TR=124 ms, in-phase TE=4.77 ms, out-of-phase TE=2.38 ms, FA=70, matrix=256 × 168, slice thickness=5 mm, interslice gap=30%, FOV=40 cm, and averages=1;
4. Axial respiratory-triggered, turbo spin-echo T2-weighted sequence with fat saturation using TR=3800 ms, TE=85 ms, FA=150, matrix=320 × 320, slice thickness=5 mm, interslice gap=30%, FOV=40 cm, and averages=1.

Diffusion-weighted MR imaging was performed before dynamic imaging, using a single-shot spin-echo Echo Planar Imaging (EPI) sequence with the b factors of 50, 400, and 800 s/mm² along the three orthogonal directions. To improve the signal-to-noise ratio and for patient convenience, DWI under free-breathing was performed. The sequence was obtained free breathing using the following technical parameters TR=6200 ms, TE=95 ms, matrix=125 × 192, slices thickness=5 mm with inter-slice gap=20%, FOV=40 cm, and the average=4.

Acquisition time for the entire liver using the three different b factors was about 3.0 min. The parallel imaging algorithms (GRAPPA), with an acceleration factor of 2, were added to reduce the acquisition time. Spectral fat saturation was employed systematically to suppress the chemical-shift artifacts. ADC maps regarding isotropic images were automatically acquired and all mean ADCs of the lesions were measured on those maps.

After determination of the optimal timing for the arterial phase imaging, using the timing bolus technique, dynamic contrast-enhanced imaging was obtained after the administration of a bolus injection of the gadopentetate dimeglumine (0.1 mmol/kg of Magnevist), at a rate of 2 mL/s. We used a 3D gradient echo sequence (VIBE) with ultrafast image reconstruction, using the parallel imaging algorithms (Generalized Auto-calibrating Partially Parallel Acquisitions [GRAPPA] factor=2) in the axial plane using the following parameters; Repetition Time [TR]=4.96 ms, Echo Time [TE]=2.38 ms, flip angle=10°, matrix=256 × 146, field of view [FOV]=40 cm, slice thickness=3 mm, during a 17 s breath-holding period.

A dynamic series consisted of one pre-contrast series, followed by three successive post-contrast series, including an early arterial, late arterial, and portal phase imaging, at 31 s intervals (17 s for image acquisition with breath-holding and 14 s for re-breathing), at the start of each phase imaging followed by a 5-min delayed phase imaging. Triphasic MRI was done in 38 patients and was contraindicated in 3 patients with renal failure on haemodialysis and GFR less than 30 ml/min. Benign appearing focal lesions were subjected to follow up for 2 years to assess the stability of the size and appearance of the lesions (after 6 months then after 1 years for cysts and more setting after 2 years follow up for haemangioma).

Biopsy was done for malignant appearing lesions and correlated with the MRI findings.

Results

Fifty-two lesions were detected in the 41 patients included in our study. Twenty-nine lesions were malignant, 12 lesions were HCC and 17 lesions were metastasis according to the final histopathological study and Twenty-three lesions were benign: 8 hepatic cysts and 15 hemangiomas according to US, CT, MRI findings and follow-up.

| Hepatic masses          | No. of lesions N= 52 | ADC Values (× 10⁻³ mm²/s) | Range of ADC | Mean ADC ± SD |
|-------------------------|----------------------|----------------------------|--------------|---------------|
| Hepatic cysts           | 8                    | 2.61-3.40                 |              | 3.15 ± 0.34   |
| Hemangiomas             | 15                   | 1.60-2.50                 |              | 2.10 ± 0.25   |
| Hepatocellular carcinoma| 12                   | 0.91-176                  |              | 1.10 ± 0.32   |
| Metastasis              | 17                   | 0.75-1.25                 |              | 0.96 ± 0.23   |

Table 1: Different ADC values for benign and malignant hepatic masses.

According to the ADC values (Table 1) twenty three lesions were benign with 8 lesions were hepatic cysts (Figure 1) with mean ADC values of 3.15 ± 0.34 × 10⁻³ mm²/s and ADC range of 2.61-3.40 × 10⁻³ mm²/s and fifteen lesions were hemangiomas (Figure 2) with mean ADC values of 2.10 ± 0.25 × 10⁻³ mm²/s and ADC range of 1.60-2.50 × 10⁻³ mm²/s.
In our study twenty nine lesions were malignant: twelve lesions were HCCs (Figures 3 and 4) and showed mean ADC values of $1.10 \pm 0.32 \times 10^{-3}$ mm$^2$/s and ADC range of $0.91-1.76 \times 10^{-3}$ mm$^2$/s and seventeen lesions were metastasis (Figure 5) with mean ADC values of $0.96 \pm 0.23 \times 10^{-3}$ mm$^2$/s and ADC range of $0.75-1.25 \times 10^{-3}$ mm$^2$/s.

Figure 1: Forty three year-old man with hepatic cyst. (A) Coronal HASTE image reveals hyperintense lesion in right hepatic lobe. (B) Axial T2W FS image displays a marked hyperintense lesion. (C) Axial diffusion-weighted (b value=800 s/mm$^2$) image shows mild hyperintensity (mostly due to T2 shine through effect). (D) Apparent diffusion coefficients (ADC) shows marked hyperintensity compared with normal parenchyma with ADC value of about $3.10 \times 10^{-3}$ mm$^2$/s.

Figure 2: Thirty-two year-old woman with haemangioma. (A) Axial T2W FS image displays a hyper intense lesion. (B) Axial post-contrast 3D GRE (VIBE) shows peripheral nodular enhancement. (C) Axial diffusion-weighted (b value=800 s/mm$^2$) image reveals hyper intensity. (D) Apparent diffusion coefficients (ADC) shows mild hyper intensity compared with normal parenchyma with ADC value of about $1.80 \times 10^{-3}$ mm$^2$/s.

Figure 3: Fifty year-old man with HCC. (A) Axial T2W FS image displays a high signal intensity lesion. (B) Axial post-contrast 3D GRE (VIBE) shows heterogeneous enhancement. (C) Axial diffusion-weighted (b value=800 s/mm$^2$) image reveals mild hyperintensity. (D) Apparent diffusion coefficients (ADC) shows mixed signal intensity with ADC value of about $1.79 \times 10^{-3}$ mm$^2$/s.

Figure 4: Fifty-six year-old man with diffuse HCC of right hepatic lobe. (A) Axial T2W FS image displays a hyperintense lesion. (B) Axial post-contrast 3D GRE (VIBE) shows heterogeneous enhancement. (C) Axial diffusion-weighted (b value=800 s/mm$^2$) image reveals hyperintensity. (D) Apparent diffusion coefficients (ADC) shows hypointensity compared with normal parenchyma with ADC value of about $1.15 \times 10^{-3}$ mm$^2$/s.
gradient echo pulse sequence, MR imaging can be sensitive to the diffusion of water molecules in the tissue [16]. Diffusion restriction increases in highly cellular tissues and decreases in low cellular tissues with large extracellular space or with broken-down cellular membranes [17].

In our study, there is a significant difference in the ADC values between malignant (HCC and metastasis) hepatic masses and benign (cysts and hemangiomas) hepatic masses with low ADC in malignant masses and high ADC value in benign masses (Figure 6). The result of our study is in agreement with other studies had been published concerning the diffusion properties of focal hepatic lesions. Most of the studies revealed that ADC values of benign lesions (cysts and hemangiomas) were significantly higher than those of malignant lesions attributed to high cellularity of malignant masses [14,18,19].

Differences in cellularity between benign and malignant liver lesions resulting in different diffusion properties of water protons within these lesions are reflected by different ADC values measured by DWI. Typically, benign liver lesions like cysts or hemangiomas that are hypocellular compared to liver parenchyma allow relatively unhindered diffusion of water protons resulting in high ADC values (~2 × 10⁻³ mm²/s in hemangiomas, and ~3 × 10⁻³ mm²/s in cysts) compared to low ADC values in hypercellular malignant liver lesions such as metastases or HCCs (1.1–1.3 × 10⁻³ mm²/s in HCCs and 1.1–1.4 × 10⁻³ mm²/s in metastases) where diffusion of water protons is more restricted [9]. A published study noticed significant difference between ADCs of benign and malignant lesions (2.45 ± 0.96 × 10⁻³ and 1.08 ± 0.50 × 10⁻³ mm²/s respectively). The mean ± SD ADCs (x10⁻³ mm²/s) of the different groups of lesions were: metastases 0.94 ± 0.60, hepatocellular carcinomas 1.33 ± 0.13, hemangiomas 2.95 ± 0.67 and cysts 3.63 ± 0.56 [14].

In our study, the benign hepatic focal lesions had a mean ADC values of about 2.46 ± 0.28 × 10⁻³ mm²/s and ADC range of about 1.60-3.40 × 10⁻³ mm²/s and the malignant hepatic focal lesions showed a mean ADC values of about 1.02 ± 0.26 × 10⁻³ mm²/s and ADC range of about 0.75–1.76 × 10⁻³ mm²/s. Several studies have identified significantly lower ADC values in malignant compared to benign focal liver lesions which coincide with our results [9,14,20].

ADCs tend to be larger when using small b-values, because the signal attenuation due to diffusion plays only a minor role in that case, and ADC values are contaminated by micro-perfusion. When higher b-values are used, ADCs tend to decrease, in relation with less perfusion contamination. Also, the ADC measurements of benign and malignant hepatic masses were significantly different, which supports similar previous findings with cysts and hemangiomas had the highest ADC values while malignant masses had the lowest ADC values [21–24]. In the liver, b values of 0 and 500–600 s/mm² are typically used. Although at least two b values are required for diffusion-weighted imaging analysis, the application of a greater number of b values will improve the accuracy of the calculated ADC. The disadvantage of using multiple high b values is an associated increase in scanning time [25,26].

In our study we used three b-values of 50, 400 and 800 sec/mm² to increase the accuracy of calculated ADC values. The hepatic masses in our study showed the following ADC values; hepatic cysts showed mean ADC values of 3.15 ± 0.34 × 10⁻³ mm²/s and ADC range of 2.61-3.40 × 10⁻³ mm²/s, hemangiomas showed mean ADC values of 2.10 ± 0.25 × 10⁻³ mm²/s and ADC range of 1.60-2.50 × 10⁻³ mm²/s, HCC lesions showed mean ADC values of 1.10 ± 0.32 × 10⁻³ mm²/s and ADC range of 0.91-1.76 × 10⁻³ mm²/s and metastasis showed

**Discussion**

Diffusion describes the random (Brownian) motion of water molecules. With a very strong bipolar gradient pulse inserted into either a spin-echo pulse sequence (i.e., Stejskal-Tanner technique) or a gradient echo pulse sequence, MR imaging can be sensitive to the diffusion properties of focal hepatic lesions.

**Figure 5**: Sixty-one year-old man with multiple hepatic metastasis. (A) Axial T2W FS image reveals slight hyperintensity lesions. (B) Axial post-contrast 3D GRE (VIBE) shows heterogeneous enhancement. (C) Axial diffusion-weighted (b value=800 s/mm²) image reveals well-defined hyperintensity lesions. (D) Apparent diffusion coefficients (ADC) shows mixed signal intensity with ADC value of about 1.02 × 10⁻³ mm²/s in solid parts.

**Figure 6**: Box plots graphs of apparent diffusion coefficient (ADC) values for malignant (n=29) and benign (23) hepatic masses in our study.
mean ADC values of 0.96 ± 0.23 × 10^{-3} \text{mm}^2/\text{s} and ADC range of 0.75-1.25 × 10^{-3} \text{mm}^2/\text{s}. Our results are in agreement with those obtained by several other studies [9,14,21-24].

Quantitative measurement of ADC has been shown to be an indicator of malignancy in focal liver lesions, with a reduction in mean ADC (low signal intensity on an ADC map) of malignant lesions compared with benign lesions [9]. Bruegel et al. [9] reported that an ADC threshold of 1.63 × 10^{-3} \text{mm}^2/\text{sec} could be used to correctly characterize 88% of lesions as either benign or malignant. Other study using a threshold ADC value of 1.5 × 10^{-3} \text{mm}^2/\text{s} was able to differentiate benign from malignant lesions with 84% sensitivity and 89% specificity. Potential limitations will include necrotic and cystic metastases, where ADC might be elevated, and the diagnosis will then rely on post-contrast images [14].

In our study, we avoid to measure ADC in necrotic parts of the mixed tumor and depending only in measurement of solid component of mixed hepatic masses. A cut-off point of ADC value of 1.65 × 10^{-3} \text{mm}^2/\text{s} was able to differentiate between malignant and benign hepatic masses with 96.6% sensitivity, 95.7% specificity, and total accuracy of about 96.2%.

Conclusion

In conclusion, DWI is easy to obtain and easy to evaluate, and ADC values can differentiate between benign and malignant liver masses with high sensitivity and specificity 96.6% and 95.7%, respectively. DWI is problem solving sequence in patients with contraindications to contrast media. We recommend addition of DWI sequence to the standard MRI examination of the liver before contrast study and according to the result of our study it is a promising sequence. However, more studies with more variants of hepatic focal lesions are needed for more evaluation of DWI in characterization of hepatic masses.

Conflict of Interest

The authors declare that they have no conflict of interest.

References

1. Padia SA, Baker ME, Schaeffer CJ, Remer EM, Obuchowski NA, et al. (2009) Safety and efficacy of sonographic-guided random realtime core needle biopsy of the liver. J Clin Ultrasound 37: 138-143.
2. Appelbaum L, Kane RA, Kriskal JB, Romero J, Sonna J (2009) Focal hepatic lesions: US-guided biopsy-lessons from review of cytologic and pathologic examination results. Radiology 250: 453-458.
3. Whitmire LF, Galambos JT, Phillips VM, Sewell CW, Erwin BC, et al. (1985) Imaging-guided percutaneous hepatic biopsy: diagnostic accuracy and safety. J Clin Gastroenterol 7: 511-515.
4. Xie L, Guang Y, Ding H, Cai A, Huang Y (2011) Diagnostic value of contrast-enhanced ultrasound, computed tomography and magnetic resonance imaging for focal liver lesions: a meta-analysis. Ultrasound Med Biol 37: 854-861.
5. Wile GE, Leyendecker JR (2010) Magnetic resonance imaging of the liver: sequence optimization and artifacts. Magn Reson Imaging Clin N Am 18: 525-547.
6. Parikh T, Drew SJ, Lee VS, Wong S, Hecht EM, et al. (2008) Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging. Radiology 246: 812-822.
7. Zech CJ, Herrmann KA, Dietrich O, Horger W, Reiser MF, et al. (2008) Black-blood diffusion-weighted EPI acquisition of the liver with parallel imaging: comparison with a standard T2-weighted sequence for detection of focal liver lesions. Invest Radiol 43: 261-266.
8. Coeneegrachts K, Delanote J, TerBeeck L, Haspeslagh M, Bipat S, et al. (2014) Improved focal liver lesion detection: comparison of single-shot diffusion-weighted echoplanar and single-shot T2 weighted turbo spin echo techniques. Br J Radiol 80: 524-531.
9. Bruegel M, Holzapfel K, Gaa J, Woertler K, Waidt S, et al. (2008) Characterization of focal liver lesions by ADC measurements using a respiratory triggered diffusion-weighted single-shot echo-planar MR imaging technique. Eur Radiol 18: 477-485.
10. Nasu K, Kuroki Y, Nawano S, Kuroki S, Tsukamoto T, et al. (2006) Hepatic metastases: diffusion-weighted sensitivity encoding versus SPION-enhanced MR imaging. Radiology 239: 122-130.
11. Koh DM, Brown G, Riddell AM, Scurr E, Collins DJ, et al. (2008) Detection of colorectal hepatic metastases using MsDPDP MR imaging and diffusion-weighted imaging (DWI) alone and in combination. Eur Radiol 18: 903-910.
12. Gourtsoyianni S, Papanikolaou N, Yarmenitis S, Marias T, Karantanis A, et al. (2008) Respiratory gated diffusion-weighted imaging of the liver: value of apparent diffusion coefficient measurements in the differentiation between most commonly encountered benign and malignant focal liver lesions. Eur Radiol 18: 486-492.
13. Sun XJ, Quan XY, Huang FH, Xu YK (2005) Quantitative evaluation of diffusion-weighted magnetic resonance imaging of focal hepatic lesions. World J Gastroenterol 11: 6535.
14. Taouli B, Vilgrain V, Dumont E, Daire JL, Fan B, et al. (2003) Evaluation of liver diffusion isoxyto and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients. Radiology 226: 71-78.
15. Deng J, Miller FH, Rhee TK, Sato KT, Mulcasy MF, et al. (2006) Diffusion-weighted MR imaging for determination of hepatocellular carcinoma response to yttrium-90 radioembolization. J Vasc Interv Radiol 17: 1195-1200.
16. Stejskal EO, Tanner JE (1965) Spin diffusion measurements: spin echoes in the presence of time-dependent field gradient. J Chem Phys 42: 288-292.
17. Koh DM, Collins DJ (2007) Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR 188: 1622-1635.
18. Goshima S, Kanematsu M, Kondo H, Yokoyama R, Kajita K, et al. (2008) Diffusion-weighted imaging of the liver: optimizing b value for the detection and characterization of benign and malignant hepatic lesions. J Magn Reson Imaging 28: 691-697.
19. Coeneegrachts K, Matos C, terBeeck L, Metens T, Haspeslagh M, et al. (2009) Focal liver lesion detection and characterization: comparison of non-contrast enhanced and SPION-enhanced diffusion-weighted single-shot echo planar and turbo spin echo T2-weighted imaging. Eur J Radiol 72: 432-439.
20. Qayyum A (2009) Diffusion-weighted imaging in the abdomen and pelvis: concepts and applications. RadioGraphics 29: 1797-1810.
21. Moteki T, HoriKoshi H, Oya N, Aoki J, Endo K (2002) Evaluation of hepatic lesions: comparison of image quality and apparent diffusion coefficient values. AJR 192: 915-922.
22. Coeneegrachts K, Delanote J, TerBeeck L, Haspeslagh M, Bipat S, et al. (2009) Evaluation of true diffusion, perfusion factor, and apparent diffusion coefficient in non-necrotic liver metastases and uncomplicated liver hemangiomas using black-blood echo planar imaging. Eur J Radiol 69: 131-138.
25. Taouli B, Tolia AJ, Losada M, Babb JS, Chan ES, et al. (2007) Diffusion weighted MRI for quantification of liver fibrosis: preliminary experience. AJR 189: 799-806.

26. Taouli B, Chouli M, Martin AJ, Qayyum A, Coakley FV, et al. (2008) Chronic hepatitis: role of diffusion weighted imaging and diffusion tensor imaging for the diagnosis of liver fibrosis and inflammation. J Magn Reson Imaging 28: 89-95.